Optimal Anticoagulation during Off Pump Coronary Artery Bypass in Patients Recently Exposed to Clopidogrel
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to find an optimal range of activated clotting time (ACT) during off-pump coronary artery bypass surgery (OPCAB) yielding ischemic protection without the risk of hemorrhagic complications in patients with recent exposure to dual antiplatelet therapy. Materials and Methods: Three hundred and five patients who received aspirin and clopidogrel within 7 days of isolated multi-vessel OPCAB were retrospectively studied. Combined hemorrhagic and ischemic outcome was defined as the occurrence of 1 of the following: significant perioperative bleeding (>30% of estimated blood volume), transfusion of packed red blood cell (pRBC) ≥2 U, or myocardial infarction (MI). This was compared in relation to the tertile distribution of the time-weighted average ACT-212-291 sec (first tertile), 292-334 sec (second tertile), 335-485 sec (third tertile). Results: The amount of perioperative blood loss was 937±313 mL, 1014±340 mL, and 1076± 383 mL, respectively (p=0.022). Significantly more patients in the third tertile developed MI (4%, 4%, and 12%, respectively, p=0.034). The incidence of significant perioperative blood loss and transfusion of pRBC ≥2 U were lower in the first tertile than those of other tertiles without statistical significance. In the multivariate analysis, the first tertile was associated with a 52% risk reduction of combined hemorrhagic and ischemic outcomes (95% confidence interval: 0.25-0.92, p= 0.027). Conclusion: A lower degree of anticoagulation with a reduced initial heparin loading dose should be carefully considered for patients undergoing OPCAB who have recently been exposed to clopidogrel.
Abstract
Purpose: The aim of this study was to find an optimal range of activated clotting time (ACT) during off-pump coronary artery bypass surgery (OPCAB) yielding ischemic protection without the risk of hemorrhagic complications in patients with recent exposure to dual antiplatelet therapy. Materials and Methods: Three hundred and five patients who received aspirin and clopidogrel within 7 days of isolated multi-vessel OPCAB were retrospectively studied. Combined hemorrhagic and ischemic outcome was defined as the occurrence of 1 of the following: significant perioperative bleeding (>30% of estimated blood volume), transfusion of packed red blood cell (pRBC) ≥2 U, or myocardial infarction (MI). This was compared in relation to the tertile distribution of the time-weighted average ACT-212-291 sec (first tertile), 292-334 sec (second tertile), 335-485 sec (third tertile). Results: The amount of perioperative blood loss was 937±313 mL, 1014±340 mL, and 1076± 383 mL, respectively (p=0.022). Significantly more patients in the third tertile developed MI (4%, 4%, and 12%, respectively, p=0.034). The incidence of significant perioperative blood loss and transfusion of pRBC ≥2 U were lower in the first tertile than those of other tertiles without statistical significance. In the multivariate analysis, the first tertile was associated with a 52% risk reduction of combined hemorrhagic and ischemic outcomes (95% confidence interval: 0.25-0.92, p= 0.027). Conclusion: A lower degree of anticoagulation with a reduced initial heparin loading dose should be carefully considered for patients undergoing OPCAB who have recently been exposed to clopidogrel.
참고문헌 (38)
- Puskas JD, "Off-pump coronary artery bypass disproportionately benefits high-risk patients", Ann Thorac Surg, 88, pp.1142~1147 (2009)
- Kerendi F, "Off-pump coronary bypass surgery for high-risk patients: only in expert centers?", Curr Opin Cardiol, 23, pp.573~578 (2008)
- Diegeler A, "Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, “off-pump” technique, and conventional cardiopulmonary bypass", Circulation, 102(19), pp.III95~III100 (2000)
- MacGillivray TE, "Patency and the pump--the risks and benefits of off-pump CABG", N Engl J Med, 350, pp.3~4 (2004)
- Czerny M, "Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass", Eur J Cardiothorac Surg, 17, pp.737~742 (2000)
- D’Ancona G, "OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey", Heart Surg Forum, 4, pp.354~358 (2001)
- Donias HW, "Heparin dose, transfusion rates, and intraoperative graft patency in minimally invasive direct coronary artery bypass", Heart Surg Forum, 6, pp.176~180 (2003)
- Nader ND, "Blood product use in cardiac revascularization: comparison of on- and off-pump techniques", Ann Thorac Surg, 68, pp.1640~1643 (1999)
- Khan NE, "A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery", N Engl J Med, 350, pp.21~28 (2004)
- Rasoli S, "Optimal intraoperative anticoagulation strategy in patients undergoing off-pump coronary artery bypass", Interact Cardiovasc Thorac Surg, 14, pp.629~633 (2012)
- Hansen KH, "Antithrombotic- and anticoagulation regimens in OPCAB surgery. A Nordic survey", Scand Cardiovasc J, 39, pp.369~374 (2005)
- Ebrahimi R, "Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial", J Am Coll Cardiol, 53, pp.1965~1972 (2009)
- Nijjer SS, "Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies", Eur Heart J, 32, pp.2970~2988 (2011)
- Fox KA, "Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial", Circulation, 110, pp.1202~1208 (2004)
- Woo YJ, "Off-pump coronary artery bypass grafting attenuates postoperative bleeding associated with preoperative clopidogrel administration", Heart Surg Forum, 6, pp.282~285 (2003)
- Shim JK, "Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery", J Thorac Cardiovasc Surg, 134, pp.59~64 (2007)
- Song SW, "Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome", Circ J, 72, pp.626~632 (2008)
- Berger JS, "Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass", J Thromb Thrombolysis, 34, pp.56~64 (2012)
- Kapetanakis EI, "Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?", Circulation, 113, pp.1667~1674 (2006)
- Thygesen K, "Universal definition of myocardial infarction", Circulation, 116, pp.2634~2653 (2007)
- Mariani MA, "Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate?", Ann Thorac Surg, 67, pp.1370~1375 (1999)
- Møller CH, "Platelet function after coronary artery bypass grafting: is there a procoagulant activity after off-pump compared with on-pump surgery?", Scand Cardiovasc J, 37, pp.149~153 (2003)
- Paparella D, "Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses", Ann Thorac Surg, 89, pp.421~427 (2010)
- Parolari A, "Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery", J Thorac Cardiovasc Surg, 130, pp.303~308 (2005)
- Paparella D, "Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques", J Thorac Cardiovasc Surg, 131, pp.290~297 (2006)
- Halkos ME, "Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery", Ann Thorac Surg, 81, pp.815~819 (2006)
- Gurbuz AT, "Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study", Eur J Cardiothorac Surg, 29, pp.190~195 (2006)
- Englberger L, "Different anticoagulation strategies in off-pump coronary artery bypass operations: a European survey", Interact Cardiovasc Thorac Surg, 7, pp.378~382 (2008)
- Chew DP, "Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials", Circulation, 103, pp.961~966 (2001)
- Tolleson TR, "Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial", J Am Coll Cardiol, 41, pp.386~393 (2003)
- Brener SJ, "Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention", Circulation, 110, pp.994~998 (2004)
- Bertrand OF, "Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy", Am J Cardiol, 104, pp.1235~1240 (2009)
- Montalescot G, "Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial", Eur Heart J, 29, pp.462~471 (2008)
- Schulz S, "ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention", Eur Heart J, 31, pp.2482~2491 (2010)
- Lincoff AM, "Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb", IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators, 1997, pp.79, 286~291
- Xiao Z, "Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor", Circulation, 97, pp.251~256 (1998)
- Mascelli MA, "Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb", IIIa antagonist abciximab, 2000, pp.139, 696~703
- Murphy GJ, "Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery", Circulation, 116, pp.2544~2552 (2007)